Nephros director granted 3,574 shares in lieu of fees
Nephros Inc. director Arthur H. Amron reported an equity grant of 3,574 shares of Common Stock, issued in lieu of cash fees for board service.
Rhea-AI Filing Summary
Nephros Inc. director Arthur H. Amron reported an equity grant of 3,574 shares of Common Stock, issued in lieu of cash fees for board service. The shares were granted at no cash cost, bringing his direct Common Stock holdings to 138,456 shares after the transaction.
He also reports outstanding stock options to purchase 7,050 shares of Common Stock at an exercise price of $1.47 per share expiring on January 1, 2035, and options on 7,323 shares at $2.14 per share expiring on May 14, 2034. Footnotes indicate these options vest in equal annual installments on specified future dates.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 3,574 shares
Grant/Award
3 txns
Insider
Amron Arthur H
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 3,574 | $0.00 | $0.00 |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Common Stock — 138,456 shares (Direct);
Stock Option (Right to Buy) — 14,373 contracts (Direct)
Footnotes (3)
- F1. Shares issued to reporting person in lieu of cash fees for board service.
- F2. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.
- F3. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.
Key Figures
Equity grant: 3,574 shares
Post-transaction holdings: 138,456 shares
Option exercise price: $1.47/share
+3 more
6 metrics
Equity grant
3,574 shares
Common Stock issued in lieu of cash board fees
Post-transaction holdings
138,456 shares
Common Stock directly held after grant
Option exercise price
$1.47/share
Stock option on 7,050 underlying shares, expiring January 1, 2035
Underlying shares (option 1)
7,050 shares
Common Stock underlying $1.47 options, expiring January 1, 2035
Option exercise price
$2.14/share
Stock option on 7,323 underlying shares, expiring May 14, 2034
Underlying shares (option 2)
7,323 shares
Common Stock underlying $2.14 options, expiring May 14, 2034
Key Terms
Stock Option (Right to Buy), grant/award acquisition, in lieu of cash fees for board service, Common Stock, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
grant/award acquisition financial
"transaction_action: grant/award acquisition"
in lieu of cash fees for board service financial
"Shares issued to reporting person in lieu of cash fees for board service."
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"exercisePrice: 1.4700 and 2.1400 indicate option exercise price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Nephros (NEPH) director Arthur H. Amron report?
Arthur H. Amron reported receiving 3,574 shares of Nephros Common Stock as an equity grant. These shares were issued in lieu of cash fees for his board service, representing compensation rather than an open-market purchase or sale.
What stock options does Arthur H. Amron hold in Nephros (NEPH)?
He holds stock options linked to 7,050 shares of Common Stock at an exercise price of $1.47 expiring January 1, 2035, and options on 7,323 shares at $2.14 expiring May 14, 2034, providing potential future share acquisitions.
Is the Nephros (NEPH) insider transaction a market buy or sell?
The reported transaction is a grant/award acquisition, not a market buy or sell. Amron received 3,574 shares at a stated price of $0.00 per share as compensation, replacing cash fees for his service on the Nephros board of directors.
How do the Nephros (NEPH) option grants to Arthur H. Amron vest?
One option vests as to 2,441 shares on each of May 14, 2024, 2025, and 2026. Another vests as to 2,350 shares on each of January 1, 2025, 2026, and 2027, spreading his ability to exercise over multiple years.
AI-generated analysis. How Rhea-AI works. Not financial advice.
